The Filing Desk

Abeona Therapeutics vs Korro Bio

Abeona Therapeutics ABEO · Korro Bio KRRO · Biotechnology

Korro Bio reported revenue of $6 million in fiscal 2025, about the same as Abeona Therapeutics' $6 million in fiscal 2025. Abeona Therapeutics had an operating margin of -1536.9%, against -1906.4% at Korro Bio. Free cash flow was −$84 million at Abeona Therapeutics and −$79 million at Korro Bio.

Side by side

Abeona TherapeuticsKorro Bio
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$6M$6M
Revenue growth—181.5%
Revenue growth a year, last 5 years−10.3%−29.6%
Gross margin73.7%—
Operating margin−1,536.9%−1,906.4%
Net margin1,223.1%−1,834.5%
Free cash flow−$84M−$79M
Free cash flow margin−1,448.5%−1,237.2%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count61.1%5.3%
Last close$2.45$12.19
P/E at the last close——
Insider trades, last 12 monthssold $3.5 millionbought $2.4 million, sold $5.7 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Abeona TherapeuticsKorro Bio
Operating margin
Percent of revenue
Abeona TherapeuticsKorro Bio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Abeona TherapeuticsKorro Bio

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Abeona Therapeutics and Korro Bio pages.